Biotech Acquisition Co (Biotech Acquisition Co) Interest Expense : $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biotech Acquisition Co's interest expense for the three months ended in Sep. 2022 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biotech Acquisition Co's Operating Income for the three months ended in Sep. 2022 was $ -0.25 Mil. Biotech Acquisition Co's Interest Expense for the three months ended in Sep. 2022 was $ 0.00 Mil. Biotech Acquisition Co has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Biotech Acquisition Co Interest Expense Historical Data

The historical data trend for Biotech Acquisition Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Interest Expense Chart

Biotech Acquisition Co Annual Data

Trend

Dec20

Dec21

Interest Expense

Biotech Acquisition Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Expense	Get a 7-Day Free Trial				-	-	-	-	-

Biotech Acquisition Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biotech Acquisition Co (NAS:BIOT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biotech Acquisition Co's Interest Expense for the three months ended in Sep. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-0.25 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was $0.00 Mil.

Biotech Acquisition Co's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Biotech Acquisition Co had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 West 25th Street, 20th Floor, New York, NY, USA, 10001

Website

Biotech Acquisition Co is a blank check company.

Executives

Albert F Hummel	director, officer: Chief Investment Officer	PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc	10 percent owner	545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari	director	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry	officer: Chief Operating Officer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer	director, 10 percent owner, officer: Chief Executive Officer	545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci	officer: CFO & Treasurer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001